FDA
-
-
-
-
-
-
-
Baird on Enanta Pharmaceuticals (ENTA): 'No change to outlook on 2026 update'
-
-
-
-
-
-
-
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study
-
-
-
-
-
-
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
-
-
-
-
-
-
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
-
-
-
-
-
-
-
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
-
-
-
-
-
-
-
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
-
328,337 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

